Differential Diagnosis of Dysarthria: A Comprehensive Guide for Clinicians

Dysarthria is a motor speech disorder stemming from neurological impairments that affect the motor control of speech. These impairments disrupt the speed, strength, coordination, and range of movement of the muscles used for speech, impacting articulation, phonation, respiration, resonance, and prosody. While the content of language remains intact, the ability to clearly articulate speech is compromised, leading to reduced speech intelligibility. This article provides an in-depth review of dysarthria, focusing on its differential diagnosis, subtypes, evaluation, and management, aiming to equip healthcare professionals with the knowledge to enhance patient care.

Understanding Dysarthria: Etiology and Classification

Dysarthria arises from a wide array of neurological conditions affecting different levels of the nervous system, from the cerebral cortex to peripheral nerves and muscles involved in speech production. Identifying the underlying cause is crucial for effective management and differential diagnosis.

Etiopathological Causes of Dysarthria:

1. Infections: Conditions like Creutzfeldt-Jakob disease and HIV-associated neurological disorders can manifest with dysarthria.
2. Vascular Disorders: Stroke (ischemic and hemorrhagic) and arteriovenous malformations are significant causes, often leading to acute onset dysarthria.
3. Neoplasms: Brain tumors, both primary and metastatic, can disrupt motor pathways and speech centers.
4. Demyelinating Diseases: Multiple sclerosis and Guillain-Barré syndrome can affect nerve conduction and muscle function, leading to dysarthria.
5. Degenerative Diseases: Parkinson’s disease (PD), progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, Huntington’s disease (HD), and ataxia-telangiectasia are progressive conditions frequently associated with dysarthria.
6. Trauma: Traumatic brain injury (TBI), chronic traumatic encephalopathy, and cerebral palsy are significant causes, with varying presentations depending on the injury location and severity.
7. Toxic Exposures: Heavy metal poisoning (e.g., Minamata disease from methylmercury), alcohol, and certain drugs can induce neurological damage resulting in dysarthria.
8. Genetic Disorders: Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO) syndrome, caused by mutations in the POLG1 gene, exemplifies genetic etiologies.

It’s important to differentiate dysarthria from articulation difficulties arising from non-neurological conditions such as cleft lip/palate or laryngeal tumors, which are not classified as dysarthria.

Table: Mayo Clinic Classification of Dysarthria by Location

This table, originally from the source article, categorizes dysarthria types based on the neurological site of lesion, aiding in differential diagnosis.

Epidemiology of Dysarthria:

The exact incidence of dysarthria is challenging to pinpoint due to varying underlying causes. However, prevalence data highlights the significant impact of this disorder:

• Approximately 90% of individuals with Parkinson’s disease develop dysarthria throughout their illness.
• In Amyotrophic Lateral Sclerosis (ALS), dysarthria can precede limb weakness by several years, affecting about 70% of patients with limb involvement.
• Studies in stroke populations indicate that dysarthria is present in a significant proportion, with some studies reporting dysarthria alone in 24% and combined with aphasia in 28% of stroke patients.
• Among children with neuromuscular diseases, the prevalence of dysarthria is estimated to be around 31.5%.
• Following traumatic brain injury, dysarthria is estimated to occur in 10% to 60% of cases.

Pathophysiology: Neural Pathways of Speech Production

Understanding the complex neural pathways controlling speech is essential for comprehending the pathophysiology of dysarthria. Speech production involves intricate coordination across five subsystems: respiration, phonation, resonance, articulation, and prosody.

Motor control for speech originates in the cerebral cortex and descends via the corticobulbar tract to cranial nerve nuclei in the brainstem. Key cranial nerves involved include:

• Facial Nerve (VII): Innervates facial muscles, crucial for articulation, particularly the lower face.
• Glossopharyngeal Nerve (IX): Supplies the stylopharyngeus muscle and pharyngeal muscles, contributing to pharynx elevation and constriction during speech.
• Vagus Nerve (X): Innervates pharyngeal and laryngeal muscles. The superior laryngeal branch controls the cricothyroid muscle (vocal cord tension), and the recurrent laryngeal branch manages vocal cord abduction and adduction.
• Hypoglossal Nerve (XII): Provides motor innervation to intrinsic and extrinsic tongue muscles (except palatoglossus), essential for articulation.

Supralaryngeal muscles, including geniohyoid, mylohyoid, stylohyoid, and digastric muscles (anterior and posterior bellies), also play a role in tongue movement by influencing hyoid bone position.

At the neuromuscular junction, acetylcholine facilitates muscle contraction. Disorders like myasthenia gravis disrupt this process through autoantibodies, leading to muscle weakness and dysarthria.

Clinical Presentation and Subtypes of Dysarthria

The clinical presentation of dysarthria varies significantly based on the underlying neurological condition and the specific motor pathways affected. The Mayo Clinic classification provides a framework for categorizing dysarthria into distinct subtypes based on lesion location, each with characteristic speech features:

• Flaccid Dysarthria: Resulting from lower motor neuron damage. Speech is often characterized by slow rate, hypernasality, and breathy voice quality. Examples include dysarthria seen in Bell’s palsy (idiopathic facial paralysis) and Guillain-Barré syndrome.

• Spastic Dysarthria: Caused by upper motor neuron lesions, typically bilaterally. Speech is described as harsh, strained-strangled, with low pitch, slow rate, and imprecise consonants. Hypernasality and reduced intelligibility are common. Associated signs can include pseudobulbar palsy with dysphagia, hyperactive reflexes (jaw jerk), and emotional lability (pseudobulbar affect). Dysarthria-clumsy hand syndrome is a specific presentation including facial weakness, dysarthria, and limb dysmetria.

• Hypokinetic Dysarthria: Primarily associated with Parkinson’s disease, resulting from basal ganglia dysfunction and dopamine deficiency. Speech is often monotone, quiet (hypophonia), and poorly articulated, sometimes with rapid rushes of speech alternating with pauses. Other Parkinsonian features like masked facies, resting tremor, rigidity, and bradykinesia are typically present.

• Hyperkinetic Dysarthria: Linked to basal ganglia lesions and hyperkinetic movement disorders such as Huntington’s disease. Speech is characterized by variable loudness, pitch, and rate, with intermittent speech arrests or involuntary movements affecting speech.

• Ataxic Dysarthria: Resulting from cerebellar damage. Speech is often described as “scanning” – irregular rhythm with syllable explosions, impaired prosody, slow articulation with pauses between syllables, and overall speech incoordination. Ataxia in limbs and trunk may also be evident.

• Mixed Dysarthria: Occurs when damage affects multiple components of the central nervous system. Common in conditions like ALS and multiple sclerosis. Speech features are a combination of different dysarthria types, often including slow rate, disrupted prosody, strained voice, and marked hypernasality.

Evaluation and Differential Diagnosis of Dysarthria

A comprehensive evaluation is critical for accurate diagnosis and differential diagnosis of dysarthria. This process involves:

1. Detailed History: Gathering information about the onset and progression of speech difficulties, associated neurological symptoms (tremors, dysphagia, gait issues), and relevant medical history (stroke risk factors, neurodegenerative conditions, toxin exposure). Medication review is important to rule out drug-induced causes.

2. Physical Examination: A thorough neurological exam to assess motor function, reflexes, and signs of underlying neurological conditions (e.g., Parkinsonism, cerebellar signs, upper/lower motor neuron signs). Oral motor examination specifically assesses the speech mechanism, including strength, range of motion, and coordination of lips, tongue, palate, and larynx.

3. Speech Evaluation: A comprehensive speech-language pathology assessment is crucial. It includes:

   • Oral Motor/Speech Mechanism Exam: Detailed assessment of the structure and function of oral musculature.
   • Subsystem Screening: Evaluation of respiration, phonation, articulation, resonance, and prosody. The water glass manometer test can provide a gross measure of respiratory support for speech.
   • Perceptual Assessment: Listening to and analyzing speech characteristics using standardized passages like the “Caterpillar Passage” or “Grandfather Passage” to evaluate speech subsystems and identify perceptual features of dysarthria subtypes.

   The Caterpillar Passage is useful for assessing various aspects of speech production in dysarthria evaluation.

   • Intelligibility Evaluation: Standardized tests such as the Assessment of Intelligibility in Dysarthric Speakers (AIDS), Sentence Intelligibility Test (SIT), and word intelligibility tests quantify speech intelligibility.

4. Bedside Tests: Simple tests can provide valuable information:

   • Counting 1-100: Assesses respiratory and phonatory endurance, particularly useful for identifying respiratory muscle fatigue in conditions like myasthenia gravis.
   • Sustained “Ah”: Evaluates laryngeal function and vocal quality.

5. Imaging and Laboratory Studies:

   • Neuroimaging: CT or MRI of the brain are often initial steps to identify structural lesions (stroke, tumor, demyelination).
   • Electromyography (EMG) and Nerve Conduction Studies (NCS): Indicated when neuromuscular junction disorders (e.g., myasthenia gravis) or peripheral neuropathies are suspected.
   • Blood and Urine Tests: CBC, BMP, and urine drug screen may be considered based on clinical context. Pulmonary function tests (vital capacity, negative inspiratory force) are important in suspected Guillain-Barré syndrome.

6. Speech Assessment Tools: Standardized assessment tools like the Frenchay Dysarthria Assessment (FDA-2) can aid in identifying dysarthria subtypes and quantifying speech impairments across different domains. Self-report questionnaires like the Living with Dysarthria (LwD) assess the patient’s perception of their communication difficulties and quality of life impact.

Differential Diagnosis:

The differential diagnosis of dysarthria includes other conditions that affect communication, primarily:

• Aphasia: A language disorder resulting from cortical damage, affecting language comprehension and/or production. Unlike dysarthria, aphasia involves linguistic deficits, impacting reading and writing in addition to spoken language.

• Apraxia of Speech (AOS): A motor speech disorder affecting the planning and programming of movements for speech, in the absence of muscle weakness. AOS is characterized by inconsistent articulatory errors, sound distortions, groping articulatory movements, and difficulty with volitional speech. In contrast to dysarthria, muscle strength and coordination are not primarily impaired in AOS; the issue lies in motor planning.

• Aphemia: A rare motor speech disorder resulting in near-muteness despite intact language comprehension, reading, and writing. It is considered a severe form of motor speech initiation difficulty, distinct from the broader motor execution deficits in dysarthria.

The table below summarizes key differentiating features to aid in the differential diagnosis:

Feature	Dysarthria	Aphasia	Apraxia of Speech (AOS)	Aphemia
Primary Deficit	Motor execution of speech	Language comprehension & formulation	Motor planning & programming of speech	Speech initiation
Muscle Weakness	Often present	Absent	Absent	Absent
Speech Sound Errors	Consistent, predictable patterns based on subtype	May occur due to language errors, not motor	Inconsistent, variable errors, sound distortions	Minimal speech output, primarily muteness
Language Content	Intact	Impaired	Intact	Intact
Comprehension	Intact	May be impaired	Intact	Intact
Reading/Writing	Intact	Often impaired	Intact	Intact
Associated Signs	Neurological motor signs (weakness, spasticity, etc.)	Language-related deficits (paraphasias, etc.)	Groping, articulatory struggle	None specific

Management and Treatment Strategies for Dysarthria

The primary goals of dysarthria management are to improve communication effectiveness, reduce communication barriers, and enhance the patient’s quality of life. Treatment strategies are individualized based on the etiology, severity, and subtype of dysarthria, and often involve a multidisciplinary team including speech-language pathologists, neurologists, and rehabilitation physicians.

Broad categories of intervention include:

1. Speech-Production Subsystem Therapy:

   • Respiration: Techniques to improve breath support for speech, such as postural adjustments and respiratory muscle strength training.
   • Phonation: Voice therapy techniques to improve vocal loudness and quality. Lee Silverman Voice Treatment (LSVT LOUD) is a well-established program for hypokinetic dysarthria in Parkinson’s disease, focusing on increasing vocal loudness. Pitch Limiting Voice Treatment aims to increase loudness without raising pitch.
   • Articulation: Exercises to improve articulatory precision, rate control, and intelligibility, including exaggerating articulation, using pauses, and altering speech rate.
   • Resonance: Strategies to manage hypernasality, such as palatal strengthening exercises or prosthetic devices (palatal lift in severe cases).
   • Prosody: Techniques to improve intonation, rhythm, and stress patterns in speech to enhance naturalness and intelligibility.

2. Communication Strategies:

   • Patient-Specific Strategies: Slowing speech rate, speaking in shorter phrases, using gestures and facial expressions, gaining listener’s attention before speaking, and repeating or rephrasing when misunderstood.
   • Communication Partner Strategies: Creating a quiet environment, maintaining eye contact, paying close attention, asking clarifying yes/no questions, and providing feedback.
   • Speech Supplementation: Techniques like alphabet supplementation (pointing to the first letter of each word on an alphabet board), topic supplementation (introducing the topic before speaking), and syntactic supplementation (providing grammatical cues) can enhance comprehension.

3. Environmental Adaptations: Modifying the communication environment to minimize distractions, reduce background noise, ensure good lighting, and promote face-to-face interaction.

4. Augmentative and Alternative Communication (AAC):

   • Low-Tech AAC: Picture boards, communication books, alphabet boards, pen and paper for written communication.
   • High-Tech AAC: Speech-generating devices (SGDs), smartphones, tablets with communication apps, voice synthesizers. Computer-based interventions and apps are increasingly being developed to support dysarthria management and practice.

5. Medical and Surgical Interventions:

   • Pharmacological Management: Addressing the underlying neurological condition (e.g., dopaminergic therapy for Parkinson’s disease). However, medication effects on dysarthria can be variable. Spasticity management in ALS with baclofen or botulinum toxin may be considered.
   • Surgical Options: Deep brain stimulation (DBS) in Parkinson’s disease may have variable effects on speech, sometimes worsening dysarthria. Laryngoplasty may be considered for hoarseness due to vocal cord paralysis. Palatal lift prostheses can surgically improve resonance in cases of palatal weakness.

6. Telerehabilitation (TR): Telehealth approaches have become increasingly important, particularly since the COVID-19 pandemic. Telerehabilitation has shown to be effective and cost-efficient for delivering speech therapy for dysarthria, offering increased accessibility and convenience.

Prognosis and Complications of Dysarthria

The prognosis for dysarthria varies depending on the underlying etiology. Dysarthria is considered chronic if it persists for more than 5 years. In non-progressive conditions, dysarthria may be stable. Recovery rates vary, with some stroke studies indicating recovery in about half of dysarthria patients. However, dysarthria is often progressive in neurodegenerative diseases.

Complications of dysarthria extend beyond communication impairment:

• Psychosocial Impact: Dysarthria can significantly impact psychosocial well-being, leading to stigmatization, altered self-identity, social isolation, emotional distress, and reduced participation in social activities. Tools like the Dysarthria Impact Profile (DIP) and Communicative Participation Item Bank (CPIB) assess these psychosocial effects.
• Educational and Vocational Impact: In children, dysarthria can hinder educational progress and future employment opportunities.

Early and comprehensive intervention is crucial to mitigate these potential far-reaching consequences and improve the overall quality of life for individuals with dysarthria.

Interprofessional Team and Healthcare Outcomes

Effective management of dysarthria requires a collaborative interprofessional team:

• Neurologists: Diagnose and manage the underlying neurological conditions.
• Speech-Language Pathologists (SLPs): Conduct comprehensive speech evaluations, provide tailored therapy, and manage AAC.
• Physiatrists (Rehabilitation Physicians): Oversee rehabilitation plans and coordinate care.
• Nurses: Play a crucial role in recognizing speech difficulties, facilitating communication, and coordinating care within inpatient settings.
• Social Workers: Provide support and connect patients and families with resources and support groups.

Professional organizations like the Academy of Neurologic Communication Disorders and Sciences (ANCDS) and the American Speech-Language-Hearing Association (ASHA) provide practice guidelines and resources for dysarthria management. Evidence-based practices, including intensive speech therapy and telerehabilitation, are continuously evolving to improve outcomes for individuals with dysarthria.

Conclusion

Differential diagnosis of dysarthria is a critical step in managing this complex motor speech disorder. By understanding the various subtypes, etiologies, and differentiating features from other communication disorders like aphasia and apraxia of speech, clinicians can provide more accurate diagnoses and develop targeted treatment plans. An interprofessional approach, utilizing evidence-based speech therapy techniques, AAC strategies, and addressing the psychosocial impact of dysarthria, is essential to optimize communication and improve the quality of life for individuals affected by this challenging condition.

References

[References are the same as the original article and are listed here for completeness.]

1.Pennington L, Parker NK, Kelly H, Miller N. Speech therapy for children with dysarthria acquired before three years of age. Cochrane Database Syst Rev. 2016 Jul 18;7(7):CD006937.

2.Im YJ, Choi J, Kim YH, Chang WH. Transient Anarthria in a Patient With Non-Dominant Hemispheric Lesion: A Case Report. Brain Neurorehabil. 2022 Mar;15(1):e8.

3.PEACHER WG. The etiology and differential diagnosis of dysarthria. J Speech Disord. 1950 Sep;15(3):252-65.

4.Darley FL, Aronson AE, Brown JR. Differential diagnostic patterns of dysarthria. J Speech Hear Res. 1969 Jun;12(2):246-69.

5.Schröter-Morasch H, Ziegler W. Rehabilitation of impaired speech function (dysarthria, dysglossia). GMS Curr Top Otorhinolaryngol Head Neck Surg. 2005;4:Doc15.

6.Gáti I, Danielsson O, Jonasson J, Landtblom AM. Sensory ataxic neuropathy with dysarthria/dysphagia and ophthalmoplegia (SANDO). Two case reports. Acta Myol. 2011 Dec;30(3):188-90.

7.Tjaden K. Speech and Swallowing in Parkinson’s Disease. Top Geriatr Rehabil. 2008;24(2):115-126.

8.Tomik B, Guiloff RJ. Dysarthria in amyotrophic lateral sclerosis: A review. Amyotroph Lateral Scler. 2010;11(1-2):4-15.

9.Kooi-van Es M, Erasmus CE, de Swart BJM, Voet NBM, van der Wees PJ, de Groot IJM, van den Engel-Hoek L., studygroup Dutch pediatric rehabilitation centers. Dysphagia and Dysarthria in Children with Neuromuscular Diseases, a Prevalence Study. J Neuromuscul Dis. 2020;7(3):287-295.

10.Mitchell C, Bowen A, Tyson S, Butterfint Z, Conroy P. Interventions for dysarthria due to stroke and other adult-acquired, non-progressive brain injury. Cochrane Database Syst Rev. 2017 Jan 25;1(1):CD002088.

11.Thomas K, Minutello K, Das JM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Nov 7, 2022. Neuroanatomy, Cranial Nerve 9 (Glossopharyngeal)

12.Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019 May 02;5(1):30.

13.Enderby P. Disorders of communication: dysarthria. Handb Clin Neurol. 2013;110:273-81.

14.Venkataraman P, Tadi P, Lui F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 7, 2024. Lacunar Syndromes (Archived)

15.Morris HL. The oral manometer as a diagnostic tool in clinical speech pathology. J Speech Hear Disord. 1966 Nov;31(4):362-9.

16.Reilly J, Fisher JL. Sherlock Holmes and the strange case of the missing attribution: a historical note on “The Grandfather Passage”. J Speech Lang Hear Res. 2012 Feb;55(1):84-8.

17.Patel R, Connaghan K, Franco D, Edsall E, Forgit D, Olsen L, Ramage L, Tyler E, Russell S. “The caterpillar”: a novel reading passage for assessment of motor speech disorders. Am J Speech Lang Pathol. 2013 Feb;22(1):1-9.

18.Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, van Doorn PA, Dourado ME, Hughes RAC, Islam B, Kusunoki S, Pardo CA, Reisin R, Sejvar JJ, Shahrizaila N, Soares C, Umapathi T, Wang Y, Yiu EM, Willison HJ, Jacobs BC. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019 Nov;15(11):671-683.

19.Icht M, Bergerzon-Bitton O, Ben-David BM. Validation and cross-linguistic adaptation of the Frenchay Dysarthria Assessment (FDA-2) speech intelligibility tests: Hebrew version. Int J Lang Commun Disord. 2022 Sep;57(5):1023-1049.

20.Hartelius L, Elmberg M, Holm R, Lovberg AS, Nikolaidis S. Living with dysarthria: evaluation of a self-report questionnaire. Folia Phoniatr Logop. 2008;60(1):11-9.

21.Chiaramonte R, Vecchio M. Dysarthria and stroke. The effectiveness of speech rehabilitation. A systematic review and meta-analysis of the studies. Eur J Phys Rehabil Med. 2021 Feb;57(1):24-43.

22.Muñoz-Vigueras N, Prados-Román E, Valenza MC, Granados-Santiago M, Cabrera-Martos I, Rodríguez-Torres J, Torres-Sánchez I. Speech and language therapy treatment on hypokinetic dysarthria in Parkinson disease: Systematic review and meta-analysis. Clin Rehabil. 2021 May;35(5):639-655.

23.Sapir S, Ramig LO, Fox CM. Intensive voice treatment in Parkinson’s disease: Lee Silverman Voice Treatment. Expert Rev Neurother. 2011 Jun;11(6):815-30.

24.de Swart BJ, Willemse SC, Maassen BA, Horstink MW. Improvement of voicing in patients with Parkinson’s disease by speech therapy. Neurology. 2003 Feb 11;60(3):498-500.

25.Vogel AP, Graf LH, Magee M, Schöls L, Rommel N, Synofzik M. Home-based biofeedback speech treatment improves dysarthria in repeat-expansion SCAs. Ann Clin Transl Neurol. 2022 Aug;9(8):1310-1315.

26.Mackenzie C, Lowit A. Behavioural intervention effects in dysarthria following stroke: communication effectiveness, intelligibility and dysarthria impact. Int J Lang Commun Disord. 2007 Mar-Apr;42(2):131-53.

27.Crowe B, Machalicek W, Wei Q, Drew C, Ganz J. Augmentative and Alternative Communication for Children with Intellectual and Developmental Disability: A Mega-Review of the Literature. J Dev Phys Disabil. 2022;34(1):1-42.

28.Orozco-Arroyave JR, Vásquez-Correa JC, Klumpp P, Pérez-Toro PA, Escobar-Grisales D, Roth N, Ríos-Urrego CD, Strauss M, Carvajal-Castaño HA, Bayerl S, Castrillón-Osorio LR, Arias-Vergara T, Künderle A, López-Pabón FO, Parra-Gallego LF, Eskofier B, Gómez-Gómez LF, Schuster M, Nöth E. Apkinson: the smartphone application for telemonitoring Parkinson’s patients through speech, gait and hands movement. Neurodegener Dis Manag. 2020 Jun;10(3):137-157.

29.Palmer R, Enderby P, Hawley M. Addressing the needs of speakers with longstanding dysarthria: computerized and traditional therapy compared. Int J Lang Commun Disord. 2007 Mar;42 Suppl 1:61-79.

30.Mendoza Ramos V, Vasquez-Correa JC, Cremers R, Van Den Steen L, Nöth E, De Bodt M, Van Nuffelen G. Automatic boost articulation therapy in adults with dysarthria: Acceptability, usability and user interaction. Int J Lang Commun Disord. 2021 Sep;56(5):892-906.

31.Pinto S, Ozsancak C, Tripoliti E, Thobois S, Limousin-Dowsey P, Auzou P. Treatments for dysarthria in Parkinson’s disease. Lancet Neurol. 2004 Sep;3(9):547-56.

32.Knepley KD, Mao JZ, Wieczorek P, Okoye FO, Jain AP, Harel NY. Impact of Telerehabilitation for Stroke-Related Deficits. Telemed J E Health. 2021 Mar;27(3):239-246.

33.Vellata C, Belli S, Balsamo F, Giordano A, Colombo R, Maggioni G. Effectiveness of Telerehabilitation on Motor Impairments, Non-motor Symptoms and Compliance in Patients With Parkinson’s Disease: A Systematic Review. Front Neurol. 2021;12:627999.

34.Catrini M, Lier-DeVitto MF. Apraxia of speech and language delay: the complexity of diagnosis and treatment of symptomatic children. Codas. 2019;31(5):e20180121.

35.Sinanović O, Mrkonjić Z, Zukić S, Vidović M, Imamović K. Post-stroke language disorders. Acta Clin Croat. 2011 Mar;50(1):79-94.

36.De Cock E, Oostra K, Bliki L, Volkaerts AS, Hemelsoet D, De Herdt V, Batens K. Dysarthria following acute ischemic stroke: Prospective evaluation of characteristics, type and severity. Int J Lang Commun Disord. 2021 May;56(3):549-557.

37.Atkinson-Clement C, Letanneux A, Baille G, Cuartero MC, Véron-Delor L, Robieux C, Berthelot M, Robert D, Azulay JP, Defebvre L, Ferreira J, Eusebio A, Moreau C, Pinto S. Psychosocial Impact of Dysarthria: The Patient-Reported Outcome as Part of the Clinical Management. Neurodegener Dis. 2019;19(1):12-21.

38.Walshe M, Peach RK, Miller N. Dysarthria impact profile: development of a scale to measure psychosocial effects. Int J Lang Commun Disord. 2009 Sep-Oct;44(5):693-715.

39.Baylor C, Yorkston K, Eadie T, Kim J, Chung H, Amtmann D. The Communicative Participation Item Bank (CPIB): item bank calibration and development of a disorder-generic short form. J Speech Lang Hear Res. 2013 Aug;56(4):1190-208.

40.Spencer KA, Brown KA. Dysarthria following Stroke. Semin Speech Lang. 2018 Feb;39(1):15-24.

41.Fletcher AR, Potts MW, Borrie SA. Educational Information Improves Listener Attitudes Toward People With Dysarthria Secondary to Parkinson’s Disease. Am J Speech Lang Pathol. 2023 May 04;32(3):1099-1109.